Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-2690

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-2690). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2690 3)

Packaging label for Losartan Potassium 50 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The label shows the NDC number 68071-2690-3 and indicates a quantity of 30 tablets. It includes manufacturer details for Zhejiang Huahai Pharmaceutical Co., Ltd. in China and storage instructions to keep at controlled temperature 68-77°F. The label also features barcodes and standard warnings.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure of Losartan potassium, illustrating its molecular arrangement with multiple rings and functional groups, including a potassium ion (K+).*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with a primary endpoint over study months (0 to 66) for Atenolol (dotted line) and Losartan Potassium (solid line). The graph includes a note on adjusted risk reduction for Losartan Potassium at 13% with a p-value of 0.021, illustrating a lower cumulative percentage of patients reaching the endpoint compared to Atenolol over time.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line chart comparing the percentage of patients with fatal and non-fatal stroke over 66 study months for Atenolol and Losartan Potassium. The y-axis shows the percent patients affected, and the x-axis shows the study month. Losartan Potassium shows a lower percent compared to Atenolol, with an adjusted risk reduction of 25% (p=0.001) indicated on the graph.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A forest plot titled 'Primary Endpoint Events within Demographic Subgroups' comparing event rates and hazard ratios for Losartan Potassium versus Atenolol across various patient subgroups including age, gender, race, ISH, diabetes, and history of cardiovascular disease for primary composite and stroke (fatal/non-fatal) outcomes. The plot includes data points, confidence intervals, and sample sizes for each subgroup, with symbols sized proportionally to sample size.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The x-axis represents time in months, and the y-axis shows the percentage of patients with the event. The graph indicates a 16.1% risk reduction with Losartan Potassium compared to placebo, with a p-value of 0.022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.